Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer

被引：0

作者：

Pitta-Venkata, Prabhakar ^{[1
]}

Palacios, Bridgitte ^{[1
]}

Chen, Yihong ^{[1
]}

Viswanadhapalli, Suryavathi ^{[1
]}

Pratap, Uday P. ^{[1
]}

Luo, Yiliao ^{[1
]}

Li, Mengxing ^{[1
]}

Altwegg, Kristin ^{[1
]}

Li, Xiaonan ^{[1
]}

Suzuki, Takayoshi ^{[2
]}

Tekmal, Rajeshwar Rao ^{[1
]}

Kost, Edward ^{[1
]}

Sareddy, Gangadhara Reddy ^{[1
]}

机构：

[1] UT Hlth San Antonio, San Antonio, TX USA

[2] Kyoto Prefectural Univ Med, Kyoto, Japan

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-280

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

280

引用

页数：2

共 50 条

[41] mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy [J].

Gomez-Pinillos, Alejandro ;

Ferrari, Anna C. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 26 (03) :483-+

[42] Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy [J].

Ezhilarasan, Devaraj ;

Harini, Karthik Shree .

ORAL ONCOLOGY, 2022, 133

[43] 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors [J].

Kutz, Craig J. ;

Holshouser, Steven L. ;

Marrow, Ethan A. ;

Woster, Patrick M. .

MEDCHEMCOMM, 2014, 5 (12) :1863-1870

[44] Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A [J].

Vianello, Paola ;

Botrugno, Oronza A. ;

Cappa, Anna ;

Ciossani, Giuseppe ;

Dessanti, Paola ;

Mai, Antonello ;

Mattevi, Andrea ;

Meroni, Giuseppe ;

Minucci, Saverio ;

Thaler, Florian ;

Tortorici, Marcello ;

Trifiro, Paolo ;

Valente, Sergio ;

Villa, Manuela ;

Varasi, Mario ;

Mercurio, Ciro .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 86 :352-363

[45] Using synthetic lethality to find effective combination therapies for cancer [J].

Bernards, Rene .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)

[46] Synthetic lethality of PARP inhibitors and metformin in BRCA1 intact ovarian cancer [J].

Hijaz, M. ;

Chhina, J. ;

Dar, S. ;

Tebbe, C. ;

Al-Wahab, Z. ;

Hanna, R. K. ;

Rattan, R. ;

Munkarah, A. R. .

GYNECOLOGIC ONCOLOGY, 2015, 137 :18-18

[47] PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer [J].

Chabanon, Roman M. ;

Morel, Daphne ;

Eychenne, Thomas ;

Colmet-Daage, Leo ;

Bajrami, Ilirjana ;

Dorvault, Nicolas ;

Garrido, Marlene ;

Meisenberg, Cornelia ;

Lamb, Andrew ;

Ngo, Carine ;

Hopkins, Suzanna R. ;

Roumeliotis, Theodoros, I ;

Jouny, Samuel ;

Henon, Clemence ;

Kawai-Kawachi, Asuka ;

Astier, Clemence ;

Konde, Asha ;

Del Nery, Elaine ;

Massard, Christophe ;

Pettitt, Stephen J. ;

Margueron, Raphael ;

Choudhary, Jyoti S. ;

Almouzni, Genevieve ;

Soria, Jean-Charles ;

Deutsch, Eric ;

Downs, Jessica A. ;

Lord, Christopher J. ;

Postel-Vinay, Sophie .

CANCER RESEARCH, 2021, 81 (11) :2888-2902

[48] Significant association between KDM1A promoter hypomethylation and colorectal cancer in Han Chinese [J].

Zhong, Jie ;

Pan, Ranran ;

Ying, Xiuru ;

Wu, Boyi ;

Zhou, Cong ;

Wu, Dongping ;

Ying, Jieer ;

Duan, Shiwei .

PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (03) :532-538

[49] Synthetic lethality in cancer treatment: Current status of PARP inhibitors [J].

Calvert, A. H. .

ANNALS OF ONCOLOGY, 2011, 22 :13-13

[50] PARP Inhibitors in Breast Cancer: Bringing Synthetic Lethality to the Bedside [J].

Turk, Anita A. ;

Wisinski, Kari B. .

CANCER, 2018, 124 (12) :2498-2506

← 1 2 3 4 5 →